Primary and secondary insulin resistance

Česká verzia

Authors: Marián Mokáň; Peter Galajda
Authors place of work: I. interná klinika Jesseniovej LF UK a UN Martin, Slovenská republika
Published in the journal: Vnitř Lék 2019; 65(4): 264-272
Category:

Summary

Insulin resistance (IR) is defined as insufficient insulin metabolic effect in target tissues, including glucose utilisation in skeletal muscle, suppression of hepatic glucose production and suppression of lipolysis in fat tissue. Primary IR originates as consequence of rare monogenetic defects of insulin receptor or molecules includes to post-receptor insulin signal cascade. Secondary IR originates mainly as a result of metabolic or hormonal changes, most commonly in visceral obesity by multifactorial postreceptor inhibition of insulin signal and it is associated with metabolic syndrome and type 2 diabetes mellitus. It is also present in endocrinopathies with overproduction of contraregulatory insulin hormones (cortisol, growth hormone, catecholamines) and using of some drugs (mainly steroids, immunosuppressive treatment). In practice IR is usually diagnosed by glycemic parameters with confirmation of prediabetic states and type 2 diabetes mellitus. The healthy life style and physical activity associated with weight loss are the most important for type 2 diabetes prevention. According to actual international guidelines metformin is only antidiabetic drug which is possible to use in prediabetic states with high risk of type 2 diabetes development, mainly in obese subjects with BMI > 35 kg/m², age under 60 years and in women with history of gestational diabetes.

Keywords:

steroid treatment – type 2 diabetes mellitus

Zdroje

Mokáň M, Martinka E, Galajda P. Diabetes mellitus a vybrané metabolické ochorenia. Vydavateľstvo P+M: Martin 2008. ISBN 9788096971398.
Hegele RA. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol Metab 2003; 14(8): 371–377.
Galajda P, Mokáň M, Mokáň M jr. Metabolický syndróm a prediabetické stavy. Vnitř Lék 2013; 59(6): 453–458.
Hatting M, Tavares C, Sharabi K et al. Insulin regulation of gluconeogenesis. Ann NY Acad Sci 2018; 1411(1): 21–35. Dostupné z DOI: <http://dx.doi.org/10.1111/nyas.13435>.
Stančík M, Galajda P, Mokáň M. Metabolický syndróm, obezita a hormóny tukového tkaniva. Vydavateľstvo Quick Print: Martin 2013.
Galajda P, Mokáň M jr, Michalovičová M et al. Nádorové ochorenia a poruchy metabolizmu glukózy. Vydavateľstvo Quick Print: Martin 2014.
Di Dalmazi G, Pagotto U, Pasquali R et al. Glucocorticoids and type 2 diabetes: from physiology to pathology. J Nutr Metab 2012; 2012: 525093. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/525093>.
Pivonello R, DeLeo M, Vitale P et al. Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 2010; 92(Suppl 1): S72-S81. Dostupné z DOI: <http://dx.doi.org/10.1159/000314319>.
Scaroni C, Zilio M, Foti M et al. Glucose metabolism abnormalities in Cushing syndrome: From molecular basis to clinical management. Endocr Rev 2017; 38(3): 189–219. Dostupné z DOI: <http://dx.doi.org/10.1210/er.2016–1105>.
Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? Diab Res Clin Pract 2018; 139: 203–220. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2018.03.006>.
Fieffe S, Morange I, Petrossians P et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 2011; 164(6): 877–884. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-10–1050>.
Resmini E, Minuto F, Colao A et al. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 2009; 46(2): 85–95. Dostupné z DOI: <http://dx.doi.org/10.1007/s00592–009–0112–9>.
Ronchi C, Epaminonda P, Cappiello V et al. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002; 25(6): 502–507. Dostupné z DOI: <http://dx.doi.org/10.1007/BF03345491>.
Eisenhofer G, Siegert G, Kotzerke J et al. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytoma and paraganglioma. Horm Metab Res 2008; 40(5): 329–337. Dostupné z DOI: <http://dx.doi.org/10.1055/s-2008–1073156>.
Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocrine Practice 2009; 15(5): 469–474. Dostupné z DOI: <http://dx.doi.org/10.4158/EP08331.RAR>.
Dedinská I, Laca Ĺ, Miklušica M et al. Twelve-Month and Five-Year Analyses of Risk Factors for New-Onset Diabetes After Transplantation in a Group of Patients Homogeneous for Immunosuppression. Transplant Proc 2015; 47(6): 1831–1839. Dostupné z DOI: <http://dx.doi.org/10.1016/j.transproceed.2015.05.017.
Gomes V, Ferreira F, Guerra J et al. New-onset diabetes after kidney transplantation: Incidence and associated factors. World J Diabetes 2018; 9(7): 132–137. Dostupné z DOI: <http://dx.doi.org/10.4239/wjd.v9.i7.132>.
Mokáň M. Prehľad in vivo techník na kvantifikáciu inzulínovej senzitivity. Vnitř Lék 1995; 41(12): 84–91.
Mitrakou A, Kelley DE, Mokan M et al. Role of reduced supression of glucose productionand diminished early insulin. New Engl J Med 1992; 326(1): 22–29. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199201023260104>.
[American Diabetes Association – International Expert Group]. Diagnosis and Classification of Diabetes. Diabetes Care 2010; 33(Suppl 1): S62-S69. Dostupné z DOI: <https://doi.org/10.2337/dc10-S062>.
Faerch K, Borch-Johnsen K, Holst JJ et al. Pathophysiology and etiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 2009; 52(9): 1714–1723. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–009–1443–3>.
Galajda P, Prídavková D, Mokáň M jr et al. Metabolic syndrome, prediabetic states and prevention of type 2 diabetes. Atheroskleróza 2018; 22(1–2): 1143–1148.
Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640–1645. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644>.
Otsuki M, Kitamura T, Tamada D et al. Incompatibility between fasting and postprandial plasma glucose in patients with Cushing‘s syndrome. Endocr J 2016; 63(11): 1017–1023.Dostupné z DOI: <http://dx.doi.org/10.1507/endocrj.EJ15–0748>.
Kesiraju S, Paritala P, Rao Ch et al. New onset of diabetes after transplantation – an overview of epidemiology, mechanism of development and diagnosis. Transpl Immunol 2014; 30(1): 52–58. Dostupné z DOI: <http://dx.doi.org/10.1016/j.trim.2013.10.006>.
[American Diabetes Association]. 5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41(Suppl 1): S51-S54. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18-S005>.
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393–403. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa012512>.
Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155–161. Erratum in Diabetes Care 2004; 27(3): 856.
Sjostrom L, Lindroos AK, Peltonen M et al. [Swedish Obese Subjects Study Scientific Group]. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351(26): 2683–2693. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa035622>.
Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs 2015; 75(10): 1071–1094. Dostupné z DOI: <http://dx.doi.org/10.1007/s40265–015–0416–8>.
Jenssen T, Hartmann A. Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol 2015; 11(8): 465–477. Dostupné z DOI: <http://dx.doi.org/10.1038/nrneph.2015.59>.